GÈNE D'ANTICORPS DR4 HUMANISÉ AYANT UNE ACTIVITÉ INDUCTRICE D'APOPTOSE ET AGENT THÉRAPEUTIQUE À DOUBLE ACTION À BASE DE CELLULE T DE RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE OU DE CELLULE TUEUSE NATURELLE L'UTILISANT
The present invention relates to a humanized DR4 antibody gene having apoptosis-inducing activity, and a dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using the same and according to the present invention, a secretory DR4 scFv antibody recombinant protein synthesized by using a humanized DR4 scFv antibody gene (humanized anti-DR4 scFv) may be used as an anticancer drug specifically targeting DR4 by binding to DR4 expressed on surface of the cancer cells to induce apoptosis of the cancer cells. In addition, the chimeric antigen receptor (CAR) using the humanized DR4 scFv antibody gene is predicted to have a strong anticancer immune effect as a dual-acting cell therapeutic agent, which is capable of simultaneously inducing apoptosis in cancer cells by DR4 and exhibiting a cytotoxic effect for cytotoxic T lymphocytes or natural killer cells by binding to DR4 expressed on the surface of cancer cells, as a DR4-specific CAR-T cell or CAR-NK cell therapeutic agent.
